

# Pulmonary Arterial Hypertension (PAH) Market in China 2023

<https://marketpublishers.com/r/PB9CBC5B9DD2EN.html>

Date: May 2023

Pages: 34

Price: US\$ 675.00 (Single User License)

ID: PB9CBC5B9DD2EN

## Abstracts

Pulmonary Arterial Hypertension (PAH) is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It occurs when the pulmonary arteries, which carry blood from the heart to the lungs to pick up oxygen, become narrowed and stiff, resulting in increased resistance to blood flow and higher blood pressure in the arteries. PAH can cause symptoms such as shortness of breath, fatigue, chest pain, dizziness, and fainting. It can also lead to complications such as heart failure, blood clots, and infections. The pulmonary arterial hypertension market in China is projected to rise by USD 913.9 million by 2029, according to the latest market study results. It is anticipated to expand at a CAGR of 39.27 percent during the forecast period.

This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on pulmonary arterial hypertension can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.

The report also includes the profiles of leading companies such as Actelion Pharmaceuticals Ltd., Bayer AG, Beijing Tide Pharmaceutical Co. Ltd., GlaxoSmithKline plc, United Therapeutics Corporation.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?

Get a detailed picture of the China Pulmonary Arterial Hypertension Market

Identify segments/areas to invest in over the forecast period in the China  
Pulmonary Arterial Hypertension Market  
Understand the competitive environment, the market's leading players  
The market estimate for ease of analysis across scenarios in Excel format.  
Strategy consulting and research support for three months.  
Print authentication provided for the single-user license.

## Contents

- Part 1. Summary
- Part 2. Introduction
  - Study period
  - Geographical scope
  - Market segmentation
- Part 3. Pulmonary arterial hypertension market overview
- Part 4. Market breakdown by region
  - Central South China
  - East China
  - North China
  - Northeast China
  - Northwest China
  - Southwest China
- Part 5. Key companies
  - Actelion Pharmaceuticals Ltd.
  - Bayer AG
  - Beijing Tide Pharmaceutical Co., Ltd.
  - GlaxoSmithKline plc
  - United Therapeutics Corporation
- Part 6. Methodology

## I would like to order

Product name: Pulmonary Arterial Hypertension (PAH) Market in China 2023

Product link: <https://marketpublishers.com/r/PB9CBC5B9DD2EN.html>

Price: US\$ 675.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB9CBC5B9DD2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970